Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of CPX101 in Healthy Volunteers and Overweight or Obese Patients With Multiple Doses

NCT06545162 is registered in ClinicalTrials.gov with Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06545162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of CPX101 in Healthy Volunteers and Overweight or Obese Patients With Multiple Doses
Lead sponsor
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2024
Completion date
December 30, 2025
Enrollment
72 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity